Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation

• Status: Withdrawn
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to take a population of lung transplant recipients who meet UCLA criteria for induction chemotherapy with thymoglobulin and prospectively study weather giving the first dose intraoperatively versus postoperatively makes a difference with how patients do during and after lung transplantation.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Los Angeles
• Collaborator: Genzyme, a Sanofi Company
• Treatments: Antilymphocyte Serum; Thymoglobulin

Criteria

Inclusion Criteria:

• On a voluntary basis, all patients eligible for bilateral lung transplantation between the ages of 18-65 years (inclusive)

Exclusion Criteria:

• Have any known allergy to horse or rabbit antithymocyte polyclonal agents

• Have a preoperative platelet count less then 100,000/mm3

• Are recipients of multiple organ transplants (either simultaneous or sequential)

• Are recipients of a single lung transplantation

• Have a contraindication to rabbit antithymocyte globulin based on judgement of the investigators (i.e. bleeding diathesis or overwhelming risk of intense immunosuppression) including the following patients: greater than 65 years of age, prior diagnosis of malignancy (with the exception skin malignancies), underlying suppurative lung disease (i.e. bronchiectasis, cystic fibrosis, etc.).